Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

Through the use of surrogate markers of efficacy, neoadjuvant studies may facilitate the implementation of new treatments into clinical practice. However, disease-free survival is the current standard outcome endpoint for registration of a novel treatment. The coupling of smaller neoadjuvant 'p...

Descripción completa

Detalles Bibliográficos
Autores principales: Snoj, Natasa, Bedard, Philippe L, de Azambuja, Evandro, Cardoso, Fatima, Piccart, Martine
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687702/
https://www.ncbi.nlm.nih.gov/pubmed/19216727
http://dx.doi.org/10.1186/bcr2209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687702/
https://www.ncbi.nlm.nih.gov/pubmed/19216727
http://dx.doi.org/10.1186/bcr2209

Ejemplares similares